Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC)
Schneeweiss A, Moebus V, Tesch H, Klare P, Denkert C, Kast K, Hanusch C, Link T, Untch M, Jackisch C, Blohmer JU, Fasching P, Solbach C, Huober J, Rhiem KE, Nekljudova V, Luebbe K, Loibl S (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S303-S304
Conference Proceedings Title: ANNALS OF ONCOLOGY
Event location: , ELECTR NETWORK
DOI: 10.1016/j.annonc.2020.08.282
Authors with CRIS profile
Involved external institutions
Universitätsklinikum Gießen und Marburg (UKGM)
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH))
Germany (DE)
Centrum für Hämatologie und Onkologie Bethanien
Germany (DE)
HELIOS Kliniken
Germany (DE)
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Universitätsklinikum Köln
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
GBG Forschungs GmbH (German Breast Group)
Germany (DE)
Universitätsklinikum Carl Gustav Carus Dresden
Germany (DE)
Rotkreuzklinikum München
Germany (DE)
Universitätsklinikum Frankfurt am Main (KGU)
Germany (DE)
Sana Klinikum Offenbach
Germany (DE)
DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH))
Germany (DE)
Centrum für Hämatologie und Onkologie Bethanien
Germany (DE)
HELIOS Kliniken
Germany (DE)
How to cite
APA:
Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K.,... Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). In ANNALS OF ONCOLOGY (pp. S303-S304). , ELECTR NETWORK: AMSTERDAM: ELSEVIER.
MLA:
Schneeweiss, A., et al. "Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC)." Proceedings of the ESMO Virtual Congress, , ELECTR NETWORK AMSTERDAM: ELSEVIER, 2020. S303-S304.
BibTeX: Download